CoChat

Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Linaclotide improves abdominal pain and constipation in patients with constipation-predominant irritable bowel syndrome (IBS-C). Patients report additional bothersome abdominal symptoms of bloating and discomfort. The intention of this study was to evaluate linaclotide's efficacy in relieving IBS-C-related abdominal symptoms (bloating, discomfort, and pain) using a novel multi-item Abdominal Score (AS). METHODS: Patients with IBS-C with abdominal pain ≥3 (0–10 scale) were randomized to linaclotide 290 μg or placebo daily for 12 weeks. The AS, derived from the Diary for IBS Symptoms-Constipation, is the average of abdominal bloating, discomfort, and pain at their worst (0 = none, 10 = worst possible). The primary end point was overall change from baseline (CFB) in AS. Secondary end points included CFB in 12-week AS evaluated using cumulative distribution function and 6-week/12-week AS responder (AS improvement ≥2 points for ≥6-week/12-week). RESULTS: Overall, 614 patients (mean age 46.7 years; 81% female) were randomized. All prespecified end points showed significant benefit of linaclotide vs placebo. The mean overall CFB AS reduction for linaclotide was −1.9 vs −1.2 for placebo ( P < 0.0001); the 6-week/12-week AS responder rate was 40.5% for linaclotide vs 23.4% for placebo (odds ratio = 2.2 [95% confidence interval, 1.55–3.12; P < 0.0001]). Diarrhea was the most common treatment-emergent adverse event (linaclotide = 4.6%, placebo = 1.6%). DISCUSSION: Linaclotide significantly reduced multiple abdominal symptoms important to patients with IBS-C (bloating, discomfort, and pain) compared with placebo, as measured by a novel multi-item AS. The AS, derived from the Diary for IBS Symptoms-Constipation, should be considered for use in future IBS-C clinical studies to measure clinically meaningful improvements beyond traditional end points.

Overview

Integrity signals

Registry

Crossref · 10.14309/ajg.0000000000001334

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 56

Metadata

Authors
Chang, L., Lacy, B. E., Moshiree, B., Kassebaum, A., Abel, J. L., Hanlon, J., Bartolini, W., Boinpally, R., Bochenek, W., Fox, S. M., Mallick, M., Tripp, K., Omniewski, N., Shea, E., & Borgstein, N.
Affiliations
  • University of California, Los Angeles (US)
  • Mayo Clinic in Florida (US)
  • University of North Carolina, Atrium Health, Charlotte, North Carolina, USA;
  • Northwestern Medicine Digestive Health Center, Chicago, Illinois, USA;
  • AbbVie (United States) (US)
  • Ironwood Pharmaceuticals (United States) (US)
Corresponding author
Chang, Lin
Venue
American Journal of Gastroenterology
Published
2021-06-11
Volume
116
Issue
9
Pages
1929-1937
ISSN
  • 0002-9270 (ISSN-L)
  • 1572-0241
OpenAlex
W3198530821
Cited by
56
References
32
Citations by year
2026: 6 · 2025: 8 · 2024: 27 · 2023: 9 · 2022: 3 · 2021: 3
FWCI
9.60
Type
journal article
Language
en
Open access
Locations
  • The American Journal of Gastroenterology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
linaclotide, irritable bowel syndrome with constipation, bloating, abdominal discomfort, abdominal pain, abdominal symptoms, symptom assessment, diarrhea adverse event
MeSH terms
Guanylyl Cyclase C Agonists, Adult, Constipation, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Peptides, Severity of Illness Index, Abdominal Pain, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. https://app.cochat.ai/papers/10.14309/ajg.0000000000001334
The paper
Chang, L., Lacy, B. E., Moshiree, B., Kassebaum, A., Abel, J. L., Hanlon, J., Bartolini, W., Boinpally, R., Bochenek, W., Fox, S. M., Mallick, M., Tripp, K., Omniewski, N., Shea, E., & Borgstein, N. (2021). Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000001334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.